Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EPANOVA vs AMINOSYN 3.5%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Aminosyn 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, thereby promoting nitrogen balance and tissue repair.
As an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/d L)
Parenteral nutrition for prevention of nitrogen loss or treatment of negative nitrogen balance in patients where oral/enteral nutrition is impossible or insufficient
4 g orally once daily as 4 capsules of 1 g each with food.
Intravenous administration of 500 m L to 1000 m L per day as a 3.5% amino acid solution, typically infused at a rate of 1.25-2.5 m L/min (equivalent to 0.25-0.5 g amino acids/kg/day). Dose individualized based on nitrogen requirements and metabolic status.
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
The plasma half-life of individual amino acids varies; for total amino acid mixture, the terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic and renal function, reflecting rapid uptake into tissues and metabolism. This half-life is clinically relevant for continuous infusion scheduling.
Epanova (omega-3-carboxylic acids) is hydrolyzed by pancreatic lipase; free fatty acids are absorbed and then metabolized via beta-oxidation similarly to dietary fatty acids.
Amino acids are metabolized primarily in the liver via deamination, transamination, and urea cycle; some metabolism occurs in peripheral tissues.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Amino acids are primarily eliminated via hepatic metabolism (deamination, transamination) and renal excretion. The renal excretion accounts for approximately 5-10% of the administered dose as unchanged amino acids; the majority is metabolized, and nitrogen is excreted as urea (80-90% of nitrogen) via urine, with minor fecal losses (<5%).
Highly protein bound (>99%), primarily to albumin and to a lesser extent to alpha-1-acid glycoprotein.
Amino acids have minimal protein binding (less than 10%), primarily to albumin, but binding is negligible for pharmacokinetic purposes.
Volume of distribution approximately 0.2 L/kg, indicating limited extravascular distribution.
Volume of distribution for amino acids is approximately 0.2-0.4 L/kg, reflecting distribution primarily into extracellular fluid and lean tissue compartments. This low Vd indicates limited extravascular distribution.
Intramuscular: ~100% (absolute bioavailability not determined in humans due to lack of IV formulation; presumed complete absorption from IM site).
Intravenous: 100% bioavailability. Not applicable to other routes; oral administration is not indicated due to first-pass metabolism and variable absorption.
No dose adjustment required for renal impairment, including end-stage renal disease on dialysis.
For GFR 30-59 m L/min: reduce dose by 50% and monitor serum BUN. For GFR 15-29 m L/min: reduce dose by 75%. For GFR <15 m L/min: avoid use unless on renal replacement therapy; if used, adjust based on amino acid losses during dialysis.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for severe hepatic impairment (Child-Pugh C) due to lack of data.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and monitor ammonia levels. Child-Pugh Class C: avoid use or use with caution, reduce dose by 75% and monitor for hepatic encephalopathy.
Safety and efficacy not established in pediatric patients under 18 years; no recommended dosing.
Intravenous infusion of 1-2 g amino acids/kg/day (equivalent to 28.6-57.1 m L/kg/day of 3.5% solution). For preterm infants: start at 1 g/kg/day and advance by 0.5 g/kg/day to target 2-3 g/kg/day. Titrate based on serum amino acid profiles and growth parameters.
No specific dose adjustment recommended; use with caution due to increased risk of adverse effects and comorbidities. Monitor hepatic function closely.
No specific dose adjustment based on age alone; however, elderly patients often have reduced renal function and lean body mass. Initiate at lower end of dosing range (e.g., 0.5 g amino acids/kg/day) and titrate slowly, monitoring renal function and fluid status.
None
None
May increase LDL-C levels; monitor LDL-C during therapy.,May prolong bleeding time; use with caution in patients receiving anticoagulants or with bleeding disorders.,Risk of atrial fibrillation or flutter in patients with prior cardiovascular disease or diabetes; discontinue if symptoms occur.
Risk of metabolic acidosis,Hepatic and renal impairment may require dose adjustment,Monitor serum electrolytes, fluid balance, and ammonia levels,Do not administer if solution is cloudy or contains particulates
Hypersensitivity to Epanova or any of its components.
Hypersensitivity to any component,Inborn errors of amino acid metabolism,Severe hepatic failure or hepatic coma,Severe azotemia or uremia not related to dialysis
Epanova may be taken with or without food, but taking with a low-fat meal may improve absorption. Avoid high-fat meals as they can increase GI side effects. Grapefruit juice has no known interaction. No significant food restrictions; maintain a heart-healthy diet.
No direct food interactions, as this is administered intravenously. However, concurrent oral intake should be avoided until parenteral nutrition is adjusted. Monitor for refeeding syndrome if transitioning to oral nutrition.
Pregnancy Category C. In animal reproduction studies, oral administration of icosapent ethyl to pregnant rats and rabbits during organogenesis at doses up to 5 and 7 times the human dose (based on body surface area) did not reveal evidence of harm to the fetus. However, there are no adequate and well-controlled studies in pregnant women. Fetal risk cannot be ruled out; use only if potential benefit justifies potential risk.
Aminosyn 3.5% is an amino acid solution used for parenteral nutrition. No specific teratogenic risk has been established in human pregnancy; however, maternal malnutrition may pose risks. During pregnancy, use only if clearly needed due to the risk of electrolyte imbalances, fluid overload, or metabolic disturbances that could affect the fetus. There are no adequate studies in pregnant women. The potential for fetal harm based on animal reproduction studies is not available.
Excretion into human milk unknown. M/P ratio not available. Caution should be exercised when administered to a nursing mother. Because many drugs are excreted in human milk, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
It is not known whether amino acids from Aminosyn 3.5% are excreted in human breast milk. The M/P ratio is not established. Caution should be exercised when administered to a nursing woman, as the effect on the breastfed infant is unknown. Consider the benefits of breastfeeding and the mother's need for the drug.
No specific dosing adjustments are recommended during pregnancy based on pharmacokinetic changes. The pharmacokinetics of icosapent ethyl have not been studied in pregnant women. Dose should be individualized based on triglyceride levels and tolerability.
Dosing adjustments may be necessary due to increased plasma volume and altered protein metabolism in pregnancy. Increased requirements for certain amino acids (e.g., threonine, lysine) may need to be considered. Monitor nitrogen balance and adjust total amino acid dose based on maternal weight, gestational age, and clinical response. Close monitoring of plasma amino acid levels and metabolic parameters is recommended to avoid excess or deficiency.
For patients with severe hypertriglyceridemia (≥500 mg/d L), Epanova (omega-3 carboxylic acids) reduces triglyceride levels by approximately 25-45% at doses of 2-4 g/day. Absorption is enhanced when taken with a low-fat meal; however, if meals cause GI distress, taking with food is still recommended. Avoid use in patients with known fish allergy. Monitor for atrial fibrillation or flutter, especially in elderly patients or those with cardiovascular risk factors. Dose should be adjusted for renal impairment (e GFR <30 m L/min).
AMINOSYN 3.5% is a crystalline amino acid solution used for parenteral nutrition. Monitor serum electrolytes, blood urea nitrogen (BUN), and ammonia levels. Do not administer simultaneously with blood products via same infusion line due to risk of incompatibility. Use with caution in patients with hepatic or renal impairment. Central line administration is required for concentrations >5%, but 3.5% can be infused via peripheral vein if adequately diluted and with careful monitoring for thrombophlebitis.
Take Epanova exactly as prescribed, typically 2-4 capsules once daily with food to reduce GI side effects.,Do not break, crush, or chew the capsules; swallow them whole.,Continue a low-fat diet and exercise program while on this medication.,Inform your doctor if you experience symptoms of an allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing).,Report any irregular heartbeat, chest pain, or shortness of breath immediately.,This medication may increase bleeding risk; tell your doctor if you have a bleeding disorder or take blood thinners (e.g., warfarin).,Store at room temperature away from moisture and heat.
This medication is given intravenously to provide protein when you cannot eat normally.,You may require regular blood tests to monitor kidney and liver function, as well as electrolyte levels.,Report any signs of infection at the IV site, such as redness, swelling, or warmth.,Do not stop or adjust the infusion rate without your healthcare provider's guidance.,Inform your doctor if you have diabetes, liver disease, or kidney disease.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EPANOVA vs AMINOSYN 3.5%, answered by our medical review team.
EPANOVA is a Parenteral Nutrition Solution that works by Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.. AMINOSYN 3.5% is a Parenteral Nutrition Solution that works by Aminosyn 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, thereby promoting nitrogen balance and tissue repair.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EPANOVA and AMINOSYN 3.5% depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EPANOVA is: 4 g orally once daily as 4 capsules of 1 g each with food.. The standard adult dose of AMINOSYN 3.5% is: Intravenous administration of 500 m L to 1000 m L per day as a 3.5% amino acid solution, typically infused at a rate of 1.25-2.5 m L/min (equivalent to 0.25-0.5 g amino acids/kg/day). Dose individualized based on nitrogen requirements and metabolic status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EPANOVA and AMINOSYN 3.5% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EPANOVA is classified as Category C. Pregnancy Category C. In animal reproduction studies, oral administration of icosapent ethyl to pregnant rats and rabbits during organogenesis at doses up to 5 and 7 times the huma. AMINOSYN 3.5% is classified as Category C. Aminosyn 3.5% is an amino acid solution used for parenteral nutrition. No specific teratogenic risk has been established in human pregnancy; however, maternal malnutrition may pose. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.